Abstract
Introduction
Familial hypercholesterolemia (FH) is a co-dominant monogenic disorder of lipoprotein metabolism, characterized by severely elevated levels of low-density lipoprotein cholesterol (LDL-C) from birth onwards. Treatment of FH patients with cholesterol-lowering medication, preferably initiated at a young age, is mandatory to prevent premature cardiovascular disease (CVD). During pregnancy, statins are contraindicated and it is recommended to discontinue statin therapy once a woman with FH decides to conceive (1) .
Maternal cholesterol levels (and subsequently LDL-C levels) increase with approximately 30-50% during pregnancy as a result of enhanced cholesterol synthesis in the liver, probably due to increased estrogen levels (2, 3) . In women with FH, the increase in cholesterol can be even more pronounced (4) and together with the recommended discontinuation of statin therapy, these women can exhibit severely elevated cholesterol levels during pregnancy. Several studies suggest that maternal cholesterol is transported from the maternal to the fetal circulation (5, 6) , and that lipid levels of the mother are closely aligned to those of the fetus in the first six months of pregnancy (7) . As a result, fetuses of FH mothers may also be exposed to high lipid levels in utero.
Although results from both animal and human studies suggest that maternal hypercholesterolemia during pregnancy could induce increased cardiovascular risk for the offspring (7) (8) (9) (10) (11) , studies in humans on the effect of maternal FH on cholesterol levels of the offspring show conflicting results. In a study in adult FH patients, it was shown that FH inherited from the mother slightly increased levels of total cholesterol and LDL-C in their adult offspring (12) . A small study in children showed that lipid levels and carotid intima-media-thickness (c-IMT), an established measure of subclinical atherosclerosis (13, 14) , did not differ between children with FH who inherited the disease maternally or paternally (15) . A similar study in non-FH offspring of FH parents has never been performed. Therefore, we set out to explore whether there is a difference in lipid levels or c-IMT in offspring (FH subjects as well as healthy siblings) of FH fathers compared to FH mothers in large cohorts of different age groups.
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Methods
Study Population
For the current study, participants of different Dutch cohorts were included. The first cohort consisted of children with FH and their unaffected siblings aged 0-18 years, who consecutively visited the AMC Pediatric Lipid Clinic between 1989 and July 2012 (cohort 1, n=3010). The second cohort comprised children with FH (aged 8-18 years) who participated in a randomised placebo-controlled trial to assess the efficacy and safety of pravastatin, and their healthy siblings in the same age range (cohort 2a, n=309) (16, 17) . Both the FH patients and their siblings were followed up after 10 years, and they constituted cohort 2b (n=277). The third cohort consisted of participants of a cross-sectional study in which subjects aged 18-60 years were recruited from the database of the screening organization for FH in the Netherlands, within 18 months after genetic screening (cohort 3, n=440) (18) . The study was approved by the Medical Ethical Committee of the Academic Medical Center, Amsterdam, the Netherlands. All participants of cohort 2a, 2b and 3 gave informed consent.
The diagnosis of FH in all patient cohorts was based on the presence of a documented pathogenic LDL receptor (LDLR) or apolipoprotein B (ApoB) mutation. For all mutations, functionality has been established by co-segregation analysis of pedigree data. Siblings were included if they had a documented absence of the known family mutation. FH patients and unaffected siblings were then divided into two groups: one with subjects whose mother had FH and one with subjects whose father had FH. Patients with homozygous FH or compound heterozygous FH, and subjects for whom the mode of inheritance of FH was unknown were excluded from the analyses. Information about demographic characteristics, classical risk factors and fasting lipid levels was obtained from the patient's medical records, or obtained from patients at their first visit at the AMC Pediatric Lipid Clinic.
Lipid and lipoprotein levels
Lipid and lipoprotein levels were determined in fasting patients in all cohorts. Plasma total cholesterol (TC), HDL cholesterol and triglyceride (TG) levels were measured by standard methods, and LDL-C by guest, on October 14, 2017 www.jlr.org Downloaded from levels were calculated using the Friedewald formula. Plasma apo B100 (ApoB) and apo A1 (ApoA) were measured by standard methods.
DNA analysis
In all cohorts, genomic DNA was prepared from 5 mL whole blood on an AutopureLS apparatus according to a protocol provided by the manufacturer (Gentra Systems, Minneapolis, MN). In patients from families with a known molecular diagnosis, mutations in LDLR, APOB and PSCK9 were detected as previously described (19) . In patients with an unknown mutation in the family, mutation identification in the LDLR and APOB genes was performed by direct Sanger sequencing; identification of large rearrangements in the LDLR gene was done by multiplex ligation-dependent probe technique as described previously in more detail (19) . Sequence analysis was performed by direct sequencing with the Big Dye Terminator ABI Prism Kit, version 1.1 (Applied Biosystems, Foster City, CA).
Products of sequence reactions were run on a Genetic Analyzer 3730 (Applied Biosystems), and sequence data were analyzed by the use of the Sequencer package (GeneCodes Co, Ann Arbor, MI).
Carotid intima-media thickness
Carotid ultrasound measurements of intima-media thickness were performed in the subjects of cohort 2 (a and b), and in cohort 3. These measurements were performed according to a standardized and validated methodology as described in detail before (20) . Ultrasound measurements of cohort 2a were as the mean IMT of the right and left common carotid, the carotid bulb, and the internal carotid far wall segments.
Statistical analysis
The different cohorts were analysed separately. Differences in variables between the 'mother' and 'father' group were evaluated for the subjects with and without FH separately, as well as for the cohort as a whole. Differences in variables with a continuous or a dichotomous distribution between groups were evaluated using linear or logistic regression analyses, respectively. By means of multivariable regression analysis, we adjusted for potential confounders. The analyses were performed using the generalized estimating equation method to adjust for correlations within families.
Variables with a skewed distribution were log-transformed before statistical analyses. A Pvalue <0.05 was considered statistically significant. The analyses were performed with the SPSS package version 19 (SPSS Inc, Chicago, IL).
With cohort 1, 2b and 3, a pooled analysis was performed for LDL-C and logtransformed TG levels and with cohort 2b and 3 for c-IMT. For each of the cohorts, we calculated a mean difference and 95% confidence interval (CI), adjusted for age, sex, body-mass index (BMI), statin use, family relations and in case of c-IMT, also blood pressure. A random effects model according to the method of inverse variance was used. The forest plots were visually examined and we tested for heterogeneity of mean differences across the cohorts using the Cochran's Q test and we measured the proportion of between-cohorts differences not attributable to chance with the I 2 statistic. A Z test was performed to test the overall effect. Analyses were performed using Review Manager 5 (the Cochrane Collaboration).
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Results
General characteristics
Of the children in cohort 1 who were eligible for this study, 1664 children had a documented pathogenic LDLR or APOB mutation and in 324 siblings the specific family mutation was absent.
These 1988 children of cohort 1 could be included in the study (Supplementary Figure 1) . Of cohort 2, 211 children with molecularly proven FH and 89 unaffected siblings could be included at baseline (cohort 2a), and 192 subjects with molecularly proven FH and 78 siblings without FH could be traced after ten years and were included in cohort 2b. Of the third cohort, 267 subjects with molecularly proven FH and 102 subjects without FH were included. Because the subjects of cohort 2b were the same subjects of cohort 2a (but 10 years later), only those of cohort 2b were included in the pooled analysis. So, the total number of subjects included in the pooled analysis of lipid levels was 2962, and for the pooled analysis of c-IMT the total number was 661. Mutation distribution of the different cohorts are presented in Supplementary Tables 1-3. General characteristics of the different cohorts are presented in Table 1 . In cohort 1, FH subjects whose father had FH were comparable with those whose mother had FH. In the sibling group there were differences in smoking status between subjects whose father had FH and subjects whose mother had FH (0% versus 4.8%,respectively, P = 0.005) and in diastolic blood pressure (68.5± 5.0 mmHg versus 60.2 ± 7.9 mmHg, P = 0.001). In cohort 2a, subjects who inherited FH paternally were slightly older compared to subjects who inherited FH maternally (13.4 ± 3.0 and 12.3 ± 2.7 years, respectively; P = 0.006). After a mean follow-up period of more than 10 years (cohort 2b), more statin users were seen in the group of FH patients who inherited FH paternally compared to subjects who inherited FH maternally (92.1% versus 77.1%, respectively: P = 0.004). Both the FH group and the sibling group of cohort 3 were comparable. For patients with FH in cohort 3, median (interquartile range) duration of statin use was 0 [0-7.5] months for subjects whose mother had FH and 0 [0-9.25] months for subjects whose father had FH (p=0.956).
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Lipids and lipoproteins
In cohort 1, no differences in lipid or lipoprotein levels between children whose father had FH compared to children whose mother had FH became evident, nor in the FH group neither in the sibling group (Table 2) .
In cohort 2a, we found a significantly higher TG level in unaffected siblings whose mother Table 2 ).
In the FH group of cohort 2b, elevated LDL-C levels were observed in subjects who inherited group, none of the differences in lipid levels reached statistical significance (Table 2 ).
In the third cohort, a statistical significant elevation in TG levels in subjects who inherited FH adjusted P = 0.002), but there was no difference in the sibling group (Table 2 ).
In the pooled analysis of both the FH and sibling groups of cohort 1, 2b and 3 (n=2962, Table   3 ), no difference could be observed in LDL-C or TG levels (mean difference LDL-C of 0.02 [-0.06, 0.11] mmol/L, P = 0.60, mean difference TG of 0.07 [-0.00, 0.14] mmol/L, P = 0.08). A sub-analysis with defective LDLR mutations, deficient LDLR mutations and ApoB mutations, showed no significant differences between subjects who inherited FH paternally or maternally in any of the mutation groups, except for subjects of cohort 1 with a ApoB mutation (4.48 ± 0.59 with FH mother vs 4.12 ± 0.59 with FH father, P = 0.005) (supplementary Table 4A-C) .
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Carotid IMT
In none of the cohorts, a difference in c-IMT between subjects whose mother had FH and subjects whose father had FH could be observed, nor a trend towards a thicker c-IMT in subjects whose mother had FH (Table 2 ). In the pooled analysis (n=661), the mean difference was -0.00 [-0.01, 0.01] mm, P = 0.86 (Table 3) .
Discussion
In this study, no difference in lipid and lipoprotein levels of offspring from FH fathers as compared to FH mothers could be demonstrated. Although in some of the sub-analyses, TG levels were higher in subjects whose mother had FH, this was not consequent in all cohorts and in the pooled analysis, the difference in TG levels between those who inherited FH maternally and those who inherited the disease paternally, did not reach statistical significance. So, this finding was probably due to chance.
Also, no clear trend was shown towards a more atherogenic lipid profile in subjects whose mother had FH, and c-IMT was in fact similar in both groups.
These results are in line with two other human studies (8, 15) . Napoli et al showed that lipid levels in children from (nonFH) hypercholesterolemic mothers did not differ from those of children from normocholesterolemic mothers. However, these authors did show that atherogenesis was more pronounced in children of hypercholesterolemic mothers (8). Tonstad et al found no statistically significant differences in lipid levels and c-IMT between the children who inherited FH maternally or paternally (15) . However, it must be taken into account that both these studies were only small and might have lacked the power to detect small differences.
Our results are in contrast with an animal study, in which it was shown that ApoE knockout mice exhibited higher cholesterol levels in offspring from hypercholesterolemic mothers as compared to genomically similar animals born from wild-type mothers (21) . Moreover, in a human study of our research group which was performed previously, we found that adult FH patients who inherited FH through their mother, had slightly but significant increased levels of TC, LDL-C and ApoB compared with adult FH patients who inherited FH through their father (12) .
Although the mode of analysis of our previous and current study were comparable, there were also some differences. In our previous study, only adult patients were involved, and non-affected siblings were not included. Possibly, differences in lipid profiles as a result of inheritance pattern are more pronounced in adult patients. As the majority of our current study are children, this could explain the conflicting results. Indeed, a trend towards higher TC, LDL-C, TG and ApoB levels in those who inherited FH through their mother, is more pronounced within the adult subjects of our current study (cohort 2b and 3) than within the children (cohort 1 and 2a) . The (trends towards) differences in lipid levels were comparable in the patients with and without FH, so the explanation that non-affected sibling were included in the current study as a means to account for the discrepancies with our previous study, is less likely. Furthermore, patients with a clinical diagnosis of FH were included in the previous study as well, in contrast to our current study in which all FH patients had a molecular diagnosis, and siblings had a proven absence of the family mutation. Possibly, in the previous cohorts, in some patients a more polygenic basis might have been involved in the FH phenotype. Mitochondrial genes might have contributed to increased lipid levels and are always inherited maternally. Possibly, this might have contributed to the higher lipid levels in subjects whose mother had a FH phenotype. In our current study, in which in all patients the FH phenotype was explained by a mutation in the LDLR or APOB gene, a mitochondrial role for increased lipid levels is less likely.
Some aspects of our study merit discussion. First, as our data are a result of post hoc analyses, the different cohorts were not designed to study our hypothesis. However, as in all cohorts family history and pedigree data were questioned comprehensively as part of cardiovascular risk assessment, we feel that the details on the mode of inheritance are robust. Second, in both adult cohorts (cohort 2b and 3), a substantial part of the FH patients was using statins. As in most patients detailed information about the exact treatment and dosage was absent, we could only adjust for the confounder 'current statin use'. If FH patients in either the paternal or maternal group were using more efficacious statins because of a higher untreated cholesterol, we missed this difference and may conclude that there is no difference in treated cholesterol levels, while a difference in untreated cholesterol might indeed exist.
Although this is a serious limitation of our study, we did a sub-analysis with the patients whose exact treatment regime was known. Untreated LDL-C levels were calculated by the estimated LDL-C lowering potency of the specific lipid-lowering drug and dose, as previously described by Huijgen et al (22) , and showed no difference between patients with an FH mother as compared to patients with an FH father.
In conclusion, our current data of subjects in the mainly pediatric age range do not show a more atherogenic lipid profile or greater c-IMT in offspring from mothers with FH than offspring from fathers with FH, although offspring from FH mothers is exposed to very high LDL-C levels during a Figure 1 : Forest plots of differences in levels of low-density lipoprotein cholesterol, triglycerides and carotid intima-media thickness between subjects whose mother had FH and subjects whose father had FH 
